Sulfasalazine (brand name Azulfidine in the U.S. Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. It was believed at the time that bacterial infections were the cause of rheumatoid arthritis. Sulfasalazine is a sulfa drug a derivative of mesalazine and is formed by combining sulfapyridine and salicylate with an azo bond.
This page contains content from the copyrighted Wikipedia article "Sulfasalazine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
